ESSA Pharma Inc stock (CA2966881026): Completes cash and stock merger

ESSA Pharma Inc (EPIX) has completed a cash and stock merger, with shareholders receiving $0.1242 cash and 1.0000 shares of EPIX^ per share, as announced in recent corporate actions.

ESSA Pharma Inc, a clinical-stage biotech focused on prostate cancer treatments, has undergone a significant corporate restructuring through a cash and stock merger. Shareholders received $0.1242 in cash and 1.0000 shares of EPIX^ for each share of EPIX held, according to the corporate actions tracker on Robinhood as of May 2026. This move impacts Nasdaq-listed EPIX holders and reflects ongoing changes in the biotech sector.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: ESSA Pharma Inc
• Sector/industry: Biotechnology / Oncology
• Headquarters/country: Canada
• Core markets: North America
• Key revenue drivers: Clinical-stage drug development
• Home exchange/listing venue: Nasdaq (EPIX)
• Trading currency: USD

ESSA Pharma Inc: core business model

ESSA Pharma Inc develops novel therapies targeting prostate cancer, particularly through its proprietary VISTA platform. The company focuses on small molecule drugs that degrade androgen receptor proteins, aiming to overcome resistance in advanced cases. ESSA's lead candidate has advanced through clinical trials, positioning it in the competitive oncology space.

Headquartered in Canada with operations in the US, ESSA Pharma trades on Nasdaq under EPIX. The firm's strategy emphasizes partnerships and milestone payments, common in biotech pre-revenue stages. This model relies on successful trial outcomes and regulatory approvals for value creation.

Main revenue and product drivers for ESSA Pharma Inc

ESSA Pharma's pipeline centers on masofaniten and other VISTA compounds, targeting hormone-resistant prostate cancer. Future revenues would stem from licensing deals, royalties, and potential commercialization. The recent merger restructures share ownership, potentially streamlining capital for R&D.

Prostate cancer treatments represent a multi-billion dollar US market, with ESSA aiming to capture share via differentiated mechanisms. Clinical data readouts remain key milestones for investors tracking biotech progress.

Why ESSA Pharma Inc matters for US investors

Listed on Nasdaq, ESSA Pharma provides US investors exposure to innovative oncology drugs addressing a major health issue. With high unmet needs in prostate cancer treatment, successful developments could drive significant returns amid sector volatility.

Conclusion

The cash and stock merger marks a pivotal restructuring for ESSA Pharma Inc, altering shareholder positions while the company advances its prostate cancer pipeline. Investors should monitor upcoming clinical updates and regulatory filings for further insights. Biotech stocks like EPIX carry inherent risks tied to trial outcomes and funding needs.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.